As vantagens do Strain no acompanhamento da quimioterapia jã são documentadas e concretas.
Falta o pagamento.
Veja o argumento da ASE
Value Proposition for Payers
Potential benefits to payers associated with limited coverage of this code as detailed above include the following:
−Potential to reduce hospitalizations and overall healthcare costs in patients receiving potentially cardio toxic chemotherapy
−Opportunity to help women with advanced breast cancer (the majority of patients receiving anthracyclines, trastuzumab)
−Congruent with most payers core principle of innovation
−Low risk proposition (for example V67.2 comprised just 3% of indications for echocardiography at Saint Luke’s Mid America Heart Institute in 2014)
Americanos sempre falam em dinheiro.
E em reduções de gastos associados aos benefícios de novas tecnologias.